Toneatti C, Saïdi Y, Meiffrédy V, Tangre P, Harel M, Eliette V, Dormont J, Aboulker JP. Experience using MedDRA for global events coding in HIV clinical trials. Contemporary Clinical Trials 2006, 27:13-22.Lien PubMed

Lévy Y, Durier C, Lascaux A.S., Meiffrédy V, Gahéry-Ségard H, Goujard C , Rouzioux C, Resch M, ElHabib R, Beumont-Mauviel M, Guillet JG, Kazatchkine M, Delfraissy JF, Aboulker JP.Sustained control of viremia following therapeutic immunization in chronically HIV-1 infected individuals. AIDS 2006, 20:405-13.Lien PubMed

Durier C, Launay O, Meiffrédy V, Saïdi Y, Salmon D, Lévy Y, Guillet J-G, Pialoux G, Aboulker J-P. Clinical safety of HIV lipopeptides used as vaccines in healthy volunteers and HIV-infected adults. AIDS 2006, 20:1039-1049.Lien PubMed

Samri A, Durier C, Urrutia A, Sanchez I, Gahery-Segard H, Imbart S, Sinet M, Tartour E, Aboulker JP, Autran B, Venet A, and the ANRS ELISpot standardization group. Evaluation of the interlaboratory concordance in quantification of HIV-specific T cells with a gamma interferon enzyme-linked immunospot assay. Clin Vacc Immunol 2006, 13:684-697. Lien PubMed

Yeni P, Cooper DA, Aboulker J-P, Babiker AG, Carey D, Darbyshire JH, Floridia M, Girard P-M, Goodall RL, Hooker MH, Mijch A, Meiffrédy V, Salzberger B, Antunes F, Becker M, Boukli N, Brun-Vézinet F, Churchill D, Conway B, Chazallon C, de Wit S, Dusak B, Emery S, Flepp M, Gatell J, Hemmer R, Law M, Loveday C, Lundgren J, Manion D, Mulcahy F, Orani A, Pharo C, Ristola M, Sandstrom E, Schechter M, Schnittman S, Seligmann M, Staszewski S, Stek M, Verbiest W, Weber J, Withnall R.Virological and immunological outcomes at three years after starting antiretroviral therapy with regimens containing non-nucleoside reverse transcriptase inhibitor, protease inhibitor, or both in INITIO: open-label randomised trial. The Lancet 2006, 368:287-298. Lien PubMed

Flandre P, Pinçon C, Aboulker J-P, Brun-Vézinet F, Pialoux G, Raffi F, and Descamps D.Analyzing plasma HIV-1 RNA measurements as multiple recurrent events in clinical trials. HIV Clin Trials 2006, 7:116-124.Lien PubMed

Marcelin G, Chazallon C, Gérard L, Saïdi Y, Aboulker JP, Girard PM, Calvez V, Piketty C.External validation of atazanavir/ritonavir genotypic score in HIV-1 protease inihibitor-experienced patients. JAIDS 2006, 42:127-28.Lien PubMed

Piketty C, Gérard L, Chazallon C, Marcelin AG, Clavel FO, Taburet AM, Calvez V, Madelaine-Chambrin I, Molina JM, Aboulker JP, Girard PM.Salvage therapy with atazanavir/ritonavir combined to tenofovir in HIV-infected patients with multiple treatment failures: randomized ANRS 107 trial. Ant Ther 2006, 11:213-21.Lien PubMed

Green H, Gibb DM, Compagnucci A, Giacomet V, de Rossi A, Harper L, Saïdi Y, Castelli-Gattinara G, Pillay D, Babiker A, Aboulker J-P, Lyall H, Bacheler L, Walker AS, Debré M, Rosso R, Burger D, Della Negra M, Dunn DT, and Giaquinto C, on behalf of the Paediatric European Network for the Treatment of AIDS (PENTA).A randomised controlled trial of genotypic HIV drug resistance testing in HIV-1- infected children: the PERA (PENTA 8) Trial. Antiviral Therapy 2006, 11:857-67. Lien PubMed